-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8

Benzinga·10/20/2026 11:56:56
Listen to the news
Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.